$-0.92 EPS Expected for Protagonist Therapeutics (PTGX); Fibria Celulose SA (ADR) (FBR) Had 2 Bullish Analysts

August 21, 2017 - By Adrian Mccoy

Analysts expect Protagonist Therapeutics Inc (NASDAQ:PTGX) to report $-0.92 EPS on September, 21.They anticipate $18.15 EPS change or 95.18% from last quarter’s $-19.07 EPS. After having $-0.84 EPS previously, Protagonist Therapeutics Inc’s analysts see 9.52% EPS growth. The stock decreased 2.78% or $0.34 on August 18, reaching $11.91. About shares traded. Protagonist Therapeutics Inc (NASDAQ:PTGX) has 0.00% since August 21, 2016 and is . It has underperformed by 16.70% the S&P500.

Among 5 analysts covering Fibria Celulose (NYSE:FBR), 2 have Buy rating, 0 Sell and 3 Hold. Therefore 40% are positive. Fibria Celulose had 8 analyst reports since July 24, 2015 according to SRatingsIntel. The firm has “Buy” rating by Zacks given on Monday, August 10. J.P. Morgan upgraded the stock to “Buy” rating in Wednesday, June 14 report. Bank of America downgraded the stock to “Neutral” rating in Thursday, July 21 report. As per Monday, August 14, the company rating was upgraded by Citigroup. Morgan Stanley upgraded it to “Equal Weight” rating and $14.70 target in Friday, July 24 report. The rating was initiated by Goldman Sachs on Monday, December 14 with “Neutral”. The stock of Fibria Celulose SA (ADR) (NYSE:FBR) earned “Buy” rating by Citigroup on Friday, October 9. See Fibria Celulose SA (ADR) (NYSE:FBR) latest ratings:

14/08/2017 Broker: Citigroup Old Rating: Neutral New Rating: Buy Upgrade
14/06/2017 Broker: J.P. Morgan Rating: Buy New Target: $13.5000 Upgrade

The stock increased 0.50% or $0.06 on August 18, reaching $12.12. About shares traded. Fibria Celulose SA (ADR) (NYSE:FBR) has risen 16.20% since August 21, 2016 and is uptrending. It has underperformed by 0.50% the S&P500.

Fibria Celulose S.A. is a forestry company, which is engaged in the production of eucalyptus pulp. The company has market cap of $6.74 billion. The Firm is engaged in the production and sale of short fiber pulp from its pulp production facilities located in the cities of Aracruz (State of Espirito Santo), Tres Lagoas (State of Mato Grosso do Sul), Jacarei (State of Sao Paulo) and Eunapolis (State of Bahia). It has a 57714.29 P/E ratio. The Company’s activities are focused on the growth of renewable and forests, and the manufacture and sale of bleached eucalyptus kraft pulp.

Investors sentiment decreased to 0.95 in 2016 Q4. Its down 0.04, from 0.99 in 2016Q3. It dived, as 19 investors sold Fibria Celulose SA (ADR) shares while 43 reduced holdings. 21 funds opened positions while 38 raised stakes. 33.63 million shares or 0.52% less from 33.80 million shares in 2016Q3 were reported. Moreover, Bank Of America Corp De has 0% invested in Fibria Celulose SA (ADR) (NYSE:FBR). Cap Innovations Limited holds 18,794 shares. Blackrock Mngmt Ltd Liability Corporation holds 0% or 72,313 shares in its portfolio. Lmm Limited Liability Company holds 0.14% or 210,000 shares in its portfolio. Mckinley Mgmt Ltd Liability Delaware, a Unknown-based fund reported 1,690 shares. Fincl Grp reported 1.40M shares. Grace White Ny accumulated 705,764 shares or 1.46% of the stock. Architects accumulated 12 shares. Wells Fargo & Mn holds 169,307 shares or 0% of its portfolio. 150,510 were reported by Goldman Sachs Group Inc. Amer Research And Company invested in 200 shares or 0% of the stock. Jpmorgan Chase & Communications holds 0% of its portfolio in Fibria Celulose SA (ADR) (NYSE:FBR) for 112,958 shares. 1,845 were reported by . Morgan Stanley reported 0% in Fibria Celulose SA (ADR) (NYSE:FBR). Guggenheim Lc holds 0.01% in Fibria Celulose SA (ADR) (NYSE:FBR) or 322,649 shares.

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical firm with a peptide technology platform focused on discovering and developing new chemical entities to address significant unmet medical needs. The company has market cap of $201.31 million. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. It currently has negative earnings. The Company’s primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com